Document Detail


Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
MedLine Citation:
PMID:  23038998     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Immune tolerance induction (ITI) can eliminate factor VIII (FVIII) inhibitory antibodies that appear during FVIII replacement therapy. If first-line ITI fails, switching to a different FVIII concentrate, especially one containing von Willebrand factor (VWF), has been advocated. The objective of the study was to assess the efficacy and safety of Haemate(®) P, a plasma-derived FVIII concentrate containing high levels of VWF, as ITI in severe haemophilia A patients who had failed at least one prior ITI attempt with a different FVIII concentrate. In this multicentre, observational study, Haemate(®) P was administered at a starting dose of 83-308 IU kg(-1)  day(-1) (1500-6000 IU day(-1) ). Efficacy was assessed by standard criteria (e.g. Bethesda titre, FVIII recovery and half-life), and bleeding characteristics. Nine patients from six haemophilia centres were treated with Haemate(®) P after failing one (n = 2), two (n = 5) or three (n = 2) prior ITI courses. The median time from inhibitor detection to Haemate(®) P treatment was 5.4 years. The median Haemate(®) P dose was 134 IU kg(-1) , and the median treatment duration 32 months. During median of 47 months of follow-up, complete response, partial response and treatment failure were observed in one, three and five patients respectively. Five patients experienced seven adverse events (AEs), including two serious AEs (sepsis). Haemate(®) P was discontinued due to an AE in one patient with a partial response. Haemate(®) P salvage ITI resulted in complete or partial tolerization in four of nine patients (44%) who had failed previous ITI attempts using different FVIII concentrates.
Authors:
C Rothschild; R D'oiron; A Borel-Derlon; Y Gruel; R Navarro; C Negrier
Related Documents :
23334618 - Single injection of triamcinolone versus three repeated injections of bevacizumab for t...
23789838 - Placebo controlled randomized compared study, blind investigator between combined vacuu...
24311928 - Anti-vegf-refractory exudative age-related macular degeneration: differential response ...
23763548 - Eosinophilic keratitis in 46 eyes of 27 horses in the mid-atlantic united states (2008-...
2394048 - Experience with a new technique for managing severely overcorrected valgus high tibial ...
23334618 - Single injection of triamcinolone versus three repeated injections of bevacizumab for t...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  -     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
Centre de Référence de l'Hémophilie, Hôpital Necker - Enfants Malades AP-HP, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bone tissue response to BMP-2 adsorbed on amorphous microporous silica implants.
Next Document:  Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Kle...